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with acute pancreatitis of any cause. Because case reports and
case series are composed in retrospect, we were wondering
why the authors did not consider data from published pro-
spective cohort studies for their analysis, particularly because
this was not explicitly excluded by the study design.
A recent study2 comparing identifiable causes of acute
pancreatitis in a prospective and in a retrospective cohort
concluded that patients who were prospectively characterized
(a) undergo a more thorough investigation more often using
ultrasonography and/or magnetic resonance imaging and (b)
report a more detailed history of taking drugs possibly related
to acute pancreatitis than patients who were retrospectively
recruited. In the prospective group, more than one-half of the
patients had2 possible causes of pancreatitis, beingmostly a
combination of gallstones and drugs.2 We, therefore, believe
that a prospective study following a prespecified investiga-
tional protocol would allow a more precise patient character-
ization than retrospective data extracted frommedical records.
As recognized by the authors of the actual review in
Gastroenterology,1 the use of case reports and case series may
be prone to publication bias. It seems indeed very likely that
more often severe than mild disease courses of putative DIAP
will be prepared for publication. To reinforce this argument,
our previouslypublishedprospectivemulticenter cohort study
on patients with inflammatory bowel disease treated with
azathioprine3 identified onlymild courses of DIAPwithout any
deaths,3 as compared with only 69% mild courses and >8%
DIAP-related deaths in the overall cohort by Meczker et al.1
Although the analysis of data from adverse event reporting
systems4,5 may partially compensate for some of the limita-
tions of collected case series, they are still susceptible tounder-
reporting, selective reporting, lack of information about total
drug consumption, and many other inaccuracies.
We, therefore, support the claim of others2 that pro-
spective studies should have an important role in furthering
our knowledge of the role drugs play in the etiology of acute
pancreatitis.
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https://doi.org/10.1053/j.gastro.2021.01.206Reply. We are very grateful for the thoughts and
comments on our study of 1060 cases of drug-
induced acute pancreatitis (DIAP)1 by Teich et al.We found their concept so interesting and potentially useful
that we decided to do a complementary study to identify all
prospective studies on DIAP, reporting its severity and
mortality, because our analysis included only case reports
and case series. We aimed to determine the severity and
mortality of DIAP in published data from prospective cohort
studies on DIAP.
Therefore we performed a systematic search on January
23, 2020, in Embase, Medline via Pubmed, and Cochrane
Central with the following search key: (acute pancreatitis)
AND (prospective OR cohort) AND (drug induced). We
included prospective cohort studies with at least a subgroup
of DIAP with data on severity or mortality during screening
and selection. We excluded non-English reports, non-human
studies, conference abstracts, case reports, case series,
retrospective cohort studies, reviews, and meta-analyses.
Data on the study, author, year, implicated drugs, number
of patients, severity, and mortality rate were extracted. We
planned proportion meta-analyses on severity and mortality
rates if there were enough data or a systematic analysis if
the meta-analytical calculations were impossible.
We identified 368, 231, and 40 potentially eligible records
in Pubmed, Embase, and Cochrane Central, respectively. After
the removal of duplicate records, 553 titles were screened.
We identified 135 titles, of which 23 abstracts seemed
eligible. Only 2 studies were identified during the full-text
screening fulfilling all the eligibility criteria.2,3
The study of Teich et al reported 37 cases of azathio-
prine (AZA)-induced acute pancreatitis in consecutively
enrolled inflammatory bowel disease adult patients. All
patients were naive to AZA. No patient died from the DIAP,
and all cases were mild.3
Abu-El-Haija et al2 reported a cohort of 165 pediatric
patients with acute pancreatitis, of whom 40 had DIAP.
There were 18 culprit drugs with mercaptopurine or AZ in 4
cases. There were 24 (60%) mild, 9 (22.5%) moderate, and
7 (17.5%) severe cases, and no deaths were reported. In
particular, the study did not report on the outcomes of AZA-
induced acute pancreatitis.
We found that most studies focused on the adverse re-
actions of certain drugs or acute pancreatitis. In these
studies, DIAP represented only a small subgroup of all cases
June 2021 Correspondence 2629with very few data, lacking data on severity and mortality.
Besides, most studies used retrospective data extracted
from various databases (hospital records, disease- or drug-
specific registries).
AZA is a well-known drug with documented strong evi-
dence for causing DIAP.4 We believe that in a prospective
study run by gastroenterologists proactively detecting early
signs of pancreatitis, the severity rates of AZA-inducedAPwill
be favorable owing to early diagnosis of DIAP and prompt
discontinuation. This may partly explain the favorable out-
comes of all AZA-induced cases in the study of Teich et al.3
In our cohort of 1060 patients with DIAP, a subgroup
analysis of the 19 AZA-induced cases showed predominantly
mild disease course (16 [88.9%] mild; 0 moderate; 2 [11.1%]
severe), and no deaths occurred. The indications for the AZA
treatment were Crohn’s disease in 13 and hepatitis, autoim-
mune pancreatitis, severe eczema, ulcerative colitis, vasculitis,
unknown in 1 each. The limited data do not allow statistical
analysis. Still, these severity rates do not seem to be signifi-
cantly different from the Teich et al3 study results.
In the prospective pediatric cohort, DIAP cases were
prospectively enrolled, but there were many culprit drugs,
and the published results did not determine which drugs
were associated with poorer outcomes.2 However, the higher
severity rates reported in this small cohort are similar to our
extensive analysis’ results, although the statistical compari-
son was not possible between the two studies.
We note that none of the above studies used the Naranjo
criteria to ascertain disease.5 Therefore, the lack of un-
equivocal confirmation that the episodes of AP were drug
induced leaves some doubt.
In summary, we agree that data from high-quality
studies should have been included in our previous anal-
ysis; however, they would not have changed the results. The
result of the systematic search for prospective data showed
that these studies on DIAP are lacking; hence, they would be
warranted to understand the natural history of this impor-
tant form of acute pancreatitis. Future studies should use
the Naranjo criteria and the Badalov classification.4,5 This
could ensure that unequivocal DIAP cases are analyzed.
BÁLINT ER}OSS
Institute for Translational Medicine
Medical School
University of Pécs and
Szentágothai Research Centre
University of Pécs and





Institute for Translational Medicine
Medical School
University of Pécs and
Szentágothai Research Centre
University of Pécs and
First Department of Medicine
Medical SchoolUniversity of Pécs
Pécs, Hungary and




1. Meczker Á, et al. Gastroenterology 2020;5:1958–1961.
2. Abu-El-Haija M, et al. Pancreatology 2020;6:1103–
1108.
3. Teich N, et al. J Crohn’s Colitis 2016;1:61–68.
4. Badalov N, et al. Clin Gastroenterol Hepatol 2007;6:648–
661.
5. Naranjo CA, et al. Clin Pharmacol Ther 1981;2:239–245.Conflicts of interest
The authors disclose no conflicts.
Most current article
https://doi.org/10.1053/j.gastro.2021.02.018IL-33 in Gastric Metaplasia—
Implications for Therapeutic
TargetsDear Editors:
We read with interest the article by De Salvo et al,1
which suggested a potential role for eosinophils during the
process of metaplasia triggered by IL-33 in a chronic model
of gastritis-prone mice. The mechanisms responsible for the
progression of metaplastic mucosa to dysplasia and cancer
have always been the central problem in tumor research
field. Through the use of mouse model and neutralization
antibodies, the authors clearly demonstrated the impor-
tance of IL-33/ST2 axis in the development of chronic
inflammation and metaplasia in the stomach. In addition, the
current study also implicated eosinophils as an early, IL-33–
responsive innate immune cell population that participated
in the complex orchestration leading to spasmolytic
polypeptide-expressing metaplasia (SPEM)/intestinalized
SPEM. However, combining previous results and current
results by the same group,1–3 we still would like to raise the
following concerns.
First, if the SPEM process is induced by an early
eosinophil-dependent response, the neutralization of eo-
sinophils should result in a dramatical decrease in the
following events, including gastric inflammation and M2
macrophage infiltration. Anti–IL-5 treatment efficiently
decreased the numbers of eosinophils, both in the periph-
eral and local environments, as expected. However, anti–IL-
5 treatment only partially decreased gastric inflammation
and M2 macrophage infiltration, which was more profound
in anti-CCR3 treatment, especially for the control of M2
